Dr. Benny Santosa, SpPD

Dr.BennySantosa,SpPD-KEMD,FINASIM
ReportoftheExpertCommitteeontheDiagnosisandClassificationofDiabetesMellitus
I. Type 1 diabetes* (ß-cell destruction, usually leading to absolute insulin
deficiency)
A. Immune mediated
B. Idiopathic
II. Type 2 diabetes* (may range from predominantly insulin resistance with
relative insulin deficiency to a predominantly secretory defect with insulin
resistance)
III. Other specific types
A. Genetic defects of ß-cell function
B. Genetic defects in insulin action
C. Diseases of the exocrine pancreas
D. Endocrinopathies
E. Drug- or chemical-induced
F. Infections
G. Uncommon forms of immune-mediated diabetes
H. Other genetic syndromes sometimes associated with diabetes
IV. Gestational diabetes mellitus (GDM)
[DiabetesCare 26:S5-S20,2003]
AlgoritmePengelolaanDMTipe2diIndonesiaKONSENSUSPERKENI2015
Modifikasipolahidupsehat
HbA1c≥9.0%
HbA1c≥7.5%
HbA1c<7.5%
Gejala(-)
Monoterapi*dengansalah
satuobatdibawahini
Kombinasi2obat*dengan
mekanismekerjayangberbeda
Gejala(+)
Kombinasi2obat
Insulin± obatjenislain
•
AgonisGLP-1
•
AgonisGLP-1
•
PenghambatDPP-IV
•
PenghambatDPP-IV
•
Tiazolidindion
•
Penghambat
•
PenghambatSGLT-2
•
InsulinBasal
•
SU/Glinid
•
Kolsevelam**
•
Bromokriptin-QR
•
Penghambat
GlukosidaseAlfa
•
PenghambatSGLT-2**
•
Tiazolidindion
•
Sulfonilurea
•
Glinid
GlukosidaseAlfa
Obatlinikedua+
Metformin
Metforminatauobatlinipertamayanglain+
•
Metforminatauobatlinipertamayanglain+
Kombinasi3obat
•
AgonisGLP-1
•
PenghambatDPP-IV
•
Tiazolidindion
•
PenghambatSGLT-2
•
InsulinBasal
•
Kolsevelam**
•
Bromokriptin-QR
•
Penghambat
Kombinasi3obat
MulaiatauintensifikasiInsulin
GlukosidaseAlfa
Keterangan
*Obatyangterdaftar,pemilihandanpenggunaannya
disarankanmempertimbangkanfaktorkeuntungan,
JikaHbAc1>6.4%
dalam3bulantambahan
Jikabelummemenuhi
obatke2(kombinasi2
sasarandalam3bulan,
obat)
masukkekombinasi3obat
KonsensusPengelolaandanPencegahanDiabetesMelitusTipe2diIndonesia.2015.
Jikabelummemenuhisasaran
dalam3bulan,mulaiterapiinsulin
atauintensifikasiterapiinsulin
kerugianbiaya,danketersediaansesuaitabel11
**KolsevelambelumtersediadiIndonesia
BromokriptinQRumumnyadigunakanpadaterapi
tumorhipofisis
2013ACC/AHAGuidelineRecommendationsfor
Statin Therapy
ASCVDStatinBenefitGroups
HearthealthylifestylehabitsarethefoundationofASCVDprevention
ClinicalASCVD
• High-Intensitystatin
(age≤75years)
• Moderate-intensity
statinif>75yearsor
notacandidatefor
high-intensitystatin
LDL-C≥190mg/dL
• High-intensitystatin
• Moderate-intensity
statinifnota
candidateforhighintensitystatin
Diabetes;age40-75
years*
• Moderate-intensity
statin
Estimated10-yr
ASCVDrisk≥7.5%†;
age40-75years*
• Moderate- tohighintensitystatin
• High-intensitystatinif
estimated10year
ASCVDrisk≥7.5%
ASCVD prevention benefit of statin therapy may be less clear in other groups . Consider additional factors
influencing ASCVD risk , potential ASCVD risk benefits and adverse effects, drug-drug interactions, and patient
preferences for statin treatment.
* With LDL-C of 70-189 mg/dL
† Estimated using the Pooled Cohort Risk Assessment Equations
StoneNJ,RobinsonJ,LichtensteinAHetal.2013ACC/AHAguidelineonthetreatmentofbloodcholesteroltoreduceatheroscleroticcardiovascularriskinadults:Areportof
theAmericanCollegeofCardiology/AmericanHeartAssociationTaskForceonpracticeguidelines.Circulation.2014;129(suppl 2):S1-S45
TATALAKSANADISLIPIDEMIA
RekomendasiStatin(BerdasarkanACC/AHA2013)
5
HIGHINTENSITY
MODERATEINTENSITY
LOWINTENSITY
Penurunan LDL-C≥50%
Penurunan LDL-C30– 50%
Penurunan LDL-C<30%
Atorvastatin 40– 80mg
Rosuvastatin 20– 40mg
Atorvastatin 10– 20mg
Rosuvastatin 5– 10mg
Simvastatin20– 40mg
Pravastatin40– 80mg
Lovastatin40mg
Fluvastatin XL80mg
Fluvastatin 40mgbid
Pitavastatin 2– 4mg
Simvastatin10mg
Pravastatin10– 20mg
Lovastatin20mg
Fluvastatin 20– 40mg
Pitavastatin 1mg
ABCsoftype2diabetes:AACE/ACE2011andADA2016
Target treatment
goals
AIC
Blood pressure
(mmHg)
Cholesterol (lipids)
AACE/ACE 2011
ADA 2016
≤ 6.5%
<7.0%***
< 130/90
<140/80***
LDL-C < 100 mg/dL (<70 mg/dL an option for
patients with diabetes and coronary artery
disease)
HDL-C >40 mg/dL in men; >50 mg/dL in women
Triglycerides < 150 mg/dL
LDL-C < 100 mg/dL (<70 mg/dL for
patients with diabetes and coronary
artery disease)
HDL-C >40 mg/dL in men; >50 mg/dL
in women Triglycerides <150 mg/dL
Handelsman, et al. Endoor Pearl 2011;17 (suppl 2):1-53.
LDL-C, low-density lipoprotein-cholesterol; HDL-C, high-density lipoprotein-cholesterol; AACE/ACE, American Association of Clinical Endocrinologists/American
College of Endocrinology; ADA, American Diabetes Association.
American Diabetes Association Standards of Medical Care in Diabetes.
Glycemic targets. Diabetes Care 2016; 39 (Suppl. 1): S39-S46